Blockchain Registration Transaction Record

Quantum BioPharma's Lucid-MS Gets FDA Nod for Phase 2 MS Trial

Quantum BioPharma's Lucid-MS gets FDA clearance to start Phase 2 trial for multiple sclerosis. First-in-class PAD2 inhibitor targets demyelination. Learn more.

This FDA clearance for Lucid-MS is a crucial step toward a potential new treatment for multiple sclerosis, a disease affecting millions worldwide. Unlike current therapies that suppress the immune system, Lucid-MS targets the root cause—demyelination—which could lead to more effective and safer options for patients. For investors, this milestone de-risks the drug candidate and could significantly boost Quantum BioPharma's valuation if the trial succeeds. Moreover, the collaboration with Harvard and Massachusetts General Hospital on imaging techniques may improve how MS progression is measured, benefiting the entire medical community.